PLOS ONE

CORRECTION

Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes *in vitro* and their effect in a mouse model for multiple sclerosis

Navina L. Chrobok, John G. J. M. Bol, Cornelis A. Jongenelen, John J. P. Brevé, Said El Alaoui, Javier Fidalgo-Lopez, Guy Fournet, Benoît Joseph, Micha M. M. Wilhelmus, Benjamin Drukarch, Anne-Marie van Dam

Dr. Javier Fidalgo-Lopez, Dr. Guy Fournet, and Dr. Benoît Joseph are not included in the author byline. The contributions of these authors are as follows: Design and synthesis of BJJF078. Please view the correct author byline, affiliations, and citation here:

Navina L. Chrobok[1], John G. J. M. Bol[1], Cornelis A. Jongenelen[1], John J. P. Brevé[1], Said El Alaoui[2], Javier Fidalgo-Lopez[2, 3☯], Guy Fournet[3☯], Benoît Joseph[3☯], Micha M. M. Wilhelmus[1], Benjamin Drukarch[1], Anne-Marie van Dam[1]

☯ These authors contributed equally to this work.

1 Department of Anatomy and Neurosciences, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands, 2 Covalab, Villeurbanne, France, 3 Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Université Claude Bernard—Lyon 1, Villeurbanne, France

Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Fidalgo-Lopez J, et al. (2018) Characterization of Transglutaminase 2 activity inhibitors in monocytes *in vitro* and their effect in a mouse model for multiple sclerosis. PLoS ONE 13(4): e0196433. https://doi.org/10.1371/journal.pone.0196433

There is an error in the fifth sentence of the Materials and methods section under the subheading "Inhibition of recombinant Transglutaminase activity". The correct sentence is: The two lyophilized TG2 inhibitors (see Fig 1 for chemical structure) BJJF078 (3,4-Dimethoxy-N-(5-[4-(acryloylamino)piperidine-1-sulfonyl]-naphthalen-1-yl)-benzamide, see S1 Appendix, synthetized and provided by Covalab, Villeurbanne, France and Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Villeurbanne, France) and ERW1041E (2-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-pyrrolidine-1—carboxylic acid quinolin-3-ylmethyl ester, kindly provided by Prof C. Khosla, Stanford University, USA) [18, 22, 23] were dissolved in DMSO (stock solution: 54 mM) and stored at -80˚C.

Citation: Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Fidalgo-Lopez J, et al. (2018) Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes *in vitro* and their effect in a mouse model for multiple sclerosis. PLoS ONE 13(12): e0209522. https://doi.org/10.1371/journal.pone.0209522

Published: December 13, 2018



Fig 1. ERW1041E and BJJF078: Name and chemical structure of the TG2 inhibitors.

https://doi.org/10.1371/journal.pone.0209522.g001

In Fig 1, the heading BJFF078 should be BJJF078. The authors have provided a corrected version here.

Supporting information

S1 Appendix. Description of the synthesis of compound BJJF078.
(DOCX)

Reference

1. Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Wilhelmus MMM, et al. (2018) Characterization of Transglutaminase 2 activity inhibitors in monocytes *in vitro* and their effect in a mouse model for multiple sclerosis. PLoS ONE 13(4): e0196433. https://doi.org/10.1371/journal.pone.0196433 PMID: 29689097